Rafferty Asset Management
CTXR icon

Rafferty Asset Management’s Citius Pharmaceuticals CTXR Stock Holding History

Rafferty Asset Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,010
Closed -$46K – 1167
2022
Q2 		$46K Sell
2,010
-86
-4% -$2.36K ﹤0.01% 1106
2022
Q1 		$94K Sell
2,096
-13
-0.6% -$513 ﹤0.01% 1175
2021
Q4 		$81K Buy
2,109
+84
+4% +$3.81K ﹤0.01% 1267
2021
Q3 		$103K Buy
+2,025
New +$102K ﹤0.01% 1222

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Rafferty Asset Management's CTXR Position: Q3 2022 in Review

Rafferty Asset Management sold out of Citius Pharmaceuticals (CTXR) in Q3 2022, closing a stake of 2,010 shares — an estimated $46K sold.

Rafferty Asset Management first reported a position in CTXR in Q3 2021 and held it in 4 quarters. The position peaked at $103K in Q3 2021. 56 funds tracked by Wall St. Rank hold CTXR as of Q3 2022.

  • Rafferty Asset Management reported no remaining Citius Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 2,010 Citius Pharmaceuticals shares in Q3 2022, an estimated $46K.
  • Rafferty Asset Management first reported a position in Citius Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Rafferty Asset Management's Citius Pharmaceuticals position peaked at $103K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2022.

Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.